Ten years ago, scientists put DNA barcodes in AAV vectors, creating an approach that simplified, expedited, and streamlined AAV screening. 

Genetic engineering pioneer Kevin Esvelt’s work highlights biotechnology’s immense potential for good—but also for catastrophe.

The minority of Parkinson’s cases now known to have genetic origins are shedding light on the cellular mechanisms of all the rest, bringing researchers closer to a cause—and perhaps a cure.

With deep learning methods revolutionizing life sciences, researchers bet on de novo proteins and cell mapping models to deliver customized precision medicines.

Research traces the evolution of a gene variant that reduces the risk of Alzheimer’s disease, finding that it originally evolved in response to infectious bacteria.

Animals with human cells could provide donor organs or help us understand neuropsychiatric disorders.

M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E.S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W.G. Johnson, A.M. Lazzarini, R.C. Duvoisin, G. Di Iorio, L.I. Golbe, R.L. Nussbaum, "Mutation in the *-synuclein gene identified in families with Parkinson's disease," Science, 276:2045-7, June 27, 1997. (Cited in more than 250 papers since publication) Comments by Robert L. Nussbaum, chief of Genetic Dis

With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.

Researchers highlight protein structure considerations for designing inhibitors that target familial Parkinson’s disease mutations.

This year’s Breakthrough Prizes honor advances in CAR T cancer therapies, cystic fibrosis, and Parkinson’s disease.